Author: healthprofessionalradio

Dr. Shereen Lim, an Australia-based dentist discusses her book “Breathe, Sleep, Thrive: Discover how airway health can unlock your child’s greater health, learning, and potential.” For more information visit www.drshereenlim.com.au

Dr. Susana Banerjee, Consultant Medical Oncologist and Research Lead for the Gynecology unit at Royal Marsden NHS and lead investigator discusses results from the registration-directed RAMP 201 trial for Verastem Oncology’s lead compound oral avutometinib (VS-6766) in combination with FAK inhibitor defactinib in low-grade serous ovarian cancer (LGSOC) that was presented at the ASCO 2023 annual meeting.

Matthew D’Onofrio, co-founder, President and COO of Evoke Pharma, a specialty pharmaceutical company focused on the treatment of gastrointestinal diseases discusses GIMOTI ®, the first and only FDA-approved nasal formulation of metoclopramide that is commercially available and specifically designed to deliver a non-oral dose of metoclopramide for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis (DGP).

Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva Pharmaceutical Industries, Ltd, discusses the availability of AUSTEDO ® XR, a once-daily treatment for adults living with tardive dyskinesia and chorea associated with Huntington’s disease. Tardive dyskinesia and chorea associated with Huntington’s disease are debilitating chronic movement disorders. Tardive dyskinesia impacts 1 in 4 people who take certain mental health treatments and chorea occurs in approximately 90% of people living with HD. Dr. Hughes is here to discuss the availability of AUSTEDO ® XR, as well as recent data that was presented at the Schizophrenia International Research Society SIRS medical meeting in May 2023.

Eduardo Dunayevich, MD, Vice President, VMAT2 Franchise Leader, and Clinical Business Development Leader for Neurocrine Biosciences, Inc. discusses an involuntary movement disorder called tardive dyskinesia (TD) which is associated with prolonged use of certain mental health medicines (antipsychotics) that are used to treat depression, bipolar disorder, schizophrenia, and schizoaffective disorder. He talks about the symptoms of TD; the physical, emotional, and social impact of TD; and the importance of increasing awareness of TD, including the importance of regular screenings with a healthcare provider. For more information visit TalkAboutTD.com

Returning guest, Beth Battaglino, RN-C, CEO of HealthyWomen discusses the new survey results and outlines how those results call for encouraging better conversations between women of reproductive age and their healthcare professionals to ensure that women are being informed of their birth control options. In addition, she talks about the need to call for the development of even more innovative contraception options that meet the quickly changing needs of individuals of childbearing age.

Joe Todisco, CEO of CorMedix, a biopharmaceutical company focused on developing and commercializing therapeutic products that prevent infection and other life-threatening conditions, discusses the dangers of hospital and other related infections, as well as the urgency behind the global expansion of antimicrobial resistance, which is on the rise. He also talks about the company’s investigational catheter lock solution, DefenCath™, to reduce the risk of catheter-related bloodstream infections (CBRSIs) from central venous catheters (CVCs), which can dramatically increase hospital costs and length of stay. An NDA has been submitted to the FDA.

Dr. Patricia Hunt, PhD, Regents Professor in the School of Molecular Biosciences at Washington State University discusses her recent award, as well as her research in prenatal development and how it is impacted by aging, mistakes in meiosis, and environmental contaminants.

Dr. Peter Berglund, Chief Scientific Officer of HDT Bio, discusses the development of a next-generation RNA vaccine platform for infectious diseases and cancer. The RNA is self-replicating, meaning that it can produce a prolonged immunological effect at a much lower dose than the current RNA vaccines. The company has a COVID-19 vaccine candidate but is also focused on emerging pandemic threats and oncology indications, both in the U.S. and internationally.

Yael Shvetz, 54, shares her story of surviving a rare hemorrhagic stroke, or brain bleed, to inspire and educate other women like herself. She is part of the American Heart Association’s Go Red for Women 2023 Real Women Class of Survivors.